Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  San Francisco
US -  Boston

GLOBAL

English

SOLUTIONS

RESOURCES

ABOUT US

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  San Francisco
US -  Boston

GLOBAL

English

Novotech CRO Ranked in Top 3 for Biotech IND Approvals in South Korea According to Ministry of Food and Drug Safety (MFDS)

Novotech CRO Ranked in Top 3 for Biotech IND Approvals in South Korea According to Ministry of Food and Drug Safety (MFDS)

September 08,2020

Sydney - Australia – Novotech, the largest biotech specialist CRO in the Asia-Pacific region, is now ranked in the top three CROs in South Korea for biotech IND approvals according to Ministry of Food and Drug Safety (MFDS) data.

Novotech made the announcement at South Korea’s KONECT International Conference. (Virtual-KST September 9-11) https://www.konectintconference.org/ 

The data came from a review of IND submissions over the past 12 months and is available on the MFDS portal https://nedrug.mfds.go.kr/searchClinic.

The other CROs in the top 3 were IQVIA and Syneos.

Novotech, which was recently awarded the Frost & Sullivan 2020 Frost & Sullivan Asia-Pacific CRO Company of the Year, also ranks ahead of several other global CROs for IND approvals.

Novotech’s Executive Director Asia Operations Yooni Kim said:

"The key to our IND success ranking is our strong local knowledge and presence. Knowing the local regulatory and clinical environment and guiding our clients through the process is how we achieve these outcomes for our biotech clients.

Since we stated operations in South Korea in 2007 we have conducted 130 clinical projects across all phases, and we now have over 80 staff in the Seoul office.

Novotech also received the Australian-Korean Business Excellence Award 2020 earlier this year in recognition of the team’s capabilities."

Novotech has signed 7 formal site partnerships with key hospitals in South Korea, including Seoul National University, Asan Medical Center, Yonsei University Severance Hospital, and Ulsan University Hospital, to facilitate the project management of clinical trials and accelerate biotech drug development (https://novotech-cro.com/locations).